- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 08.06. | OS Therapies: OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma | 279 | Newsfile | Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and AustraliaPatent pending pharmacodynamic response... ► Artikel lesen | |
| 02.06. | OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings | 2 | Benzinga.com | ||
| 02.06. | OS Therapies: OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma | 720 | Newsfile | 75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated... ► Artikel lesen | |
| 29.05. | OS Therapies: OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World | 508 | Newsfile | The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarcoma... ► Artikel lesen | |
| 26.05. | OS Therapies: OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences | 502 | Newsfile | ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference:... ► Artikel lesen | |
| 18.05. | OS Therapies GAAP EPS of -$0.27 | 1 | Seeking Alpha | ||
| 18.05. | OS Therapies: OS Therapies Reports First Quarter 2026 Financials and Provides Business Update | 529 | Newsfile | $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027$4.5 million of accrued VAT refunds... ► Artikel lesen | |
| 18.05. | OS Therapies Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | OS Therapies: OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | 433 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based... ► Artikel lesen | |
| 14.05. | OS Therapies: OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor | 508 | Newsfile | Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation... ► Artikel lesen | |
| 12.05. | Reportable, Inc.: Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) | 410 | Newsfile | Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies... ► Artikel lesen | |
| 30.04. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | EMA begins rolling review of OS Therapies' osteosarcoma treatment | 1 | Investing.com | ||
| 30.04. | EMA startet fortlaufende Prüfung der Osteosarkom-Therapie von OS Therapies | 1 | Investing.com Deutsch | ||
| 30.04. | OS Therapies: OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma | 389 | Newsfile | Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating... ► Artikel lesen | |
| 27.04. | OS Therapies: OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET | 367 | Newsfile | Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up... ► Artikel lesen | |
| 16.04. | OS Therapies: OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes | 415 | Newsfile | New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference... ► Artikel lesen | |
| 13.04. | OS Therapies: OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor | 805 | Newsfile | Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with listeria... ► Artikel lesen | |
| 08.04. | OS Therapies: OS Therapies Appoints Craig Eagle, MD as Strategic Advisor | 1.103 | Newsfile | Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma regulatory advice and oncology... ► Artikel lesen | |
| 02.04. | OS Therapies: OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors | 850 | Newsfile | Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately $2 million in non-dilutive R&D tax credits... ► Artikel lesen |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,520 | -4,08 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| CRISPR THERAPEUTICS | 47,365 | +0,39 % | Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year | ||
| PALATIN TECHNOLOGIES | 10,460 | -1,41 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,202 | -1,48 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,383 | +5,80 % | NurExone stärkt globalen Patentschutz für seine Exosomen-Plattform | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,355 | +6,40 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,865 | -4,85 % | RedHill Biopharma closes $6 million private placement | ||
| IMMUNIC | 13,305 | +2,31 % | EQS-News: Immunic AG: Immunic to Participate in Investor, Industry and Scientific Conferences in June | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor, Industry and Scientific Conferences in June
10.06.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,970 | -4,92 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 | King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,455 | +2,13 % | Onco-Innovations stellt 300 g pharmazeutischen Wirkstoff für die Skalierung von ONC010 zur Unterstützung der für die IND-Zulassung erforderlichen Entwicklung her | Ernennung von Herrn Dave Antony zum CFO
Vancouver, Kanada - 19. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder... ► Artikel lesen | |
| NOVOCURE | 13,120 | +1,12 % | Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma | The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start... ► Artikel lesen | |
| PHARMING | 1,162 | +1,26 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,800 | +1,15 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| REVOLUTION MEDICINES | 157,25 | +5,15 % | Das geheime Verfahren das Krebszellen sterben lässt: Was Revolution Medicines und Merck & Co. von Vidac Pharma lernen müssen | Hier kann man ohne Übertreibung von einer Patent-Superklippe sprechen: Satte 236 Mrd. USD drohende jährliche Umsatzverluste zwingen die biopharmazeutische Industrie dazu, neue Wege zu gehen. Pharma-Riesen... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,840 | -1,39 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,795 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.